There is no much evidence on the use of levosimendan in cardiac surgery in terms of survival advantage after surgery
Commentary: The quest for the holy grail continues: Is levosimendan the best choice to support patients with cardiomyopathy requiring cardiac surgery? / Onorati, Francesco; Veraldi, Gianfranco; Faggian, Giuseppe. - In: JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. - ISSN 0022-5223. - 159:6(2020), pp. 2312-2313. [10.1016/j.jtcvs.2019.06.136]
Commentary: The quest for the holy grail continues: Is levosimendan the best choice to support patients with cardiomyopathy requiring cardiac surgery?
Onorati, Francesco;
2020-01-01
Abstract
There is no much evidence on the use of levosimendan in cardiac surgery in terms of survival advantage after surgeryFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Commentary JTCVS 2020 Levosimendan.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
113.82 kB
Formato
Adobe PDF
|
113.82 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
